Please login to the form below

Not currently logged in
Email:
Password:

eosinophilic

This page shows the latest eosinophilic news and features for those working in and with pharma, biotech and healthcare.

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

dermatitis and as add-on maintenance therapy for asthma with an eosinophilic phenotype or in patients dependent on oral corticosteroids. ... Chronic rhinosinusitis with nasal polyposis is the latest indication to be added to the label, but the two

Latest news

  • GSK’s Nucala gets boost with self-administration approval GSK’s Nucala gets boost with self-administration approval

    Fasenra and Dupixent pose threat to leader. Nucala has received a boost in the eosinophilic asthma treatment market with a newly-approved autoinjector and a pre-filled safety syringe, allowing carers ... Nucala was first approved for use in severe

  • Aimmune preps EU filing for peanut allergy immunotherapy Aimmune preps EU filing for peanut allergy immunotherapy

    CEO Jayson Dallas. No cases of serious effects such as anaphylaxis or of eosinophilic esophagitis (EoE) were observed during the study, further reinforcing AR101’s profile.

  • AstraZeneca wins NICE backing for asthma injection AstraZeneca wins NICE backing for asthma injection

    But the revised offer from AstraZeneca has led to  a broader recommendation from NICE, which will see the NHS fund its use for patients struggling to control severe eosinophilic asthma with ... Meindert Boysen, director of NICE’s Centre for Health

  • FDA rejects GSK’s Nucala for COPD FDA rejects GSK’s Nucala for COPD

    The FDA wasn’t comfortable with that idea, however, suggesting there is a lack of consensus among clinicians as to the definition of eosinophilic COPD – and whether it is actually a

  • AZ, Amgen’s first-in-class asthma drug gets breakthrough status AZ, Amgen’s first-in-class asthma drug gets breakthrough status

    However, the FDA’s BTD for tezepelumab is for patients “without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma ... used mainly in patients

More from news
Approximately 2 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Baxalta aside, it has been a busy year for Shire which in February acquired the company Meritage bringing in a phase III ready oral budesonide solution for eosinophilic oesophagitis [an orphan

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - develop and commercialise. 265. Meritage Pharma/ Shire. Phase 3-ready oral budesonide suspension (OBS) - eosinophilic esophagitis (EoE).

  • Pharma deals during March 2013 Pharma deals during March 2013

    Receptos will conduct a phase II proof-of-concept study in Eosinophilic Esophagitis, an orphan indication in the US.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics